HSIC up +0.64% percent right now. $HSIC High is at 130.07

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
HSIC up +0.64% percent right now. $HSIC High is at 130.07 and the Low 128.94 with current volume of 169,598.

Recent News posted below.

HSIC Henry Schein Recent Headline News

Cramer's Mad Money - 8 Earnings To Watch This Week (11/7/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Nov 09, 7:58AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program , Friday November 7. Earnings to watch this week: WhiteWave (NYSE: WWAV ), D.R Horton (NYSE: DRI ), Macy's (NYSE: M ), J.C. Penney (NYSE: JCP ), Cisco (NASDAQ: CSCO...
WWAV: 35.81 (-1.12), KSS: 56.72 (-0.50), JCP: 7.25 (-0.57), JWN: 72.52 (-0.91), WMT: 79.70 (+0.93), M: 59.33 (-0.55), EPR: 57.63 (+1.02), HSIC: 129.43 (+0.59), CSCO: 25.19 (-0.14), DRI: 54.06 (+0.56)

Jim Cramer's Top Stock Picks: WWAV EPR HSIC
at The Street - Sat Nov 08, 5:00AM CST
Cramer expects big things from WhiteWave Foods and is a big fan of EPR Properties and Henry Schein.
WWAV: 35.81 (-1.12), EPR: 57.63 (+1.02), HSIC: 129.43 (+0.59)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.48 (+0.35), KMI: 38.49 (-0.26), HK: 3.24 (unch), KSS: 56.72 (-0.50), GE: 26.47 (+0.06), LMT: 187.02 (+0.87), AVAV: 29.28 (-0.53), WMT: 79.70 (+0.93), SNE: 20.53 (+0.91), M: 59.33 (-0.55), SDRL: 21.65 (-0.12), T: 35.09 (+0.18), W: 26.96 (+0.95), OPK: 8.71 (+0.39), QCOM: 69.76 (+0.50), TWTR: 39.76 (-0.55), EPR: 57.63 (+1.02), AAPL: 109.05 (+0.04), HSIC: 129.43 (+0.59), CSCO: 25.19 (-0.14), WFM: 47.76 (+0.95), CY: 10.17 (+0.09), MU: 33.01 (unch), SWKS: 61.25 (+1.37), IRM: 37.56 (-0.49), BAC: 17.35 (-0.01), MO: 49.88 (+0.01), CSX: 36.50 (+1.05), WWAV: 35.81 (-1.12), GILD: 107.02 (+0.57), TXN: 51.56 (+0.66), BPL: 78.60 (-0.70), JCP: 7.25 (-0.57), JWN: 72.52 (-0.91), BABA: 119.06 (+4.50)

Henry Schein Up 12.3% Since SmarTrend Uptrend Call (HSIC)
Comtex SmarTrend(R) - Fri Nov 07, 9:26AM CST
SmarTrend identified an Uptrend for Henry Schein (NASDAQ:HSIC) on October 21st, 2014 at $115.22. In approximately 2 weeks, Henry Schein has returned 12.29% as of today's recent price of $129.37.
HSIC: 129.43 (+0.59)

Will This Price Target Increase Help Henry Schein (HSIC) Stock Today?
at The Street - Fri Nov 07, 7:59AM CST
Henry Schein's (HSIC) price target was raised at Credit Suisse.
HSIC: 129.43 (+0.59)

Henry Schein Partnership With The Professional Baseball Athletic Trainers Society (PBATS) Hosts 21 "Home Run For Health" Events In 2014
PR Newswire - Fri Nov 07, 6:00AM CST
Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, recently completed its second year of participation in the PLAY Campaign, which was held in partnership with the Professional Baseball Athletic Trainers Society® (PBATS). With a $40,000 donation from Henry Schein's Sports Medicine business and the Henry Schein Cares Foundation, Henry Schein hosted 21 "Home Run for Health" events during this year's campaign to educate children and teenagers about the importance of staying active, eating right and routine dentist and physician visits. In addition, each child received an oral hygiene kit donated by Henry Schein Cares, the global corporate social responsibility program of Henry Schein.
HSIC: 129.43 (+0.59)

Henry Schein
at Investor's Business Daily - Thu Nov 06, 5:49PM CST
Henry Schein (HSIC) Q3 earnings rose 9.8% to $1.34 a share, topping by 4 cents, and revenue edged up 11.7% to $2.62 bil, topping views for $2.55 bil. Shares of the health care product company rose 6.6% to 130.31.
HSIC: 129.43 (+0.59)

After Yesterday's Rally of 6.63% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 4:06PM CST
Henry Schein (NASDAQ:HSIC) traded in a range yesterday that spanned from a low of $122.22 to a high of $133.16. Yesterday, the shares gained 6.6%, which took the trading range above the 3-day high of $122.83 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSIC: 129.43 (+0.59)

Henry Schein Set to Possibly Pullback After Yesterday's Rally of 6.63%
Comtex SmarTrend(R) - Thu Nov 06, 4:05PM CST
Henry Schein (NASDAQ:HSIC) traded in a range yesterday that spanned from a low of $122.22 to a high of $133.16. Yesterday, the shares gained 6.6%, which took the trading range above the 3-day high of $122.83 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSIC: 129.43 (+0.59)

Henry Schein's (HSIC) CEO Stanley Bergman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 2:20PM CST

HSIC: 129.43 (+0.59)

Henry Schein (HSIC) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:55AM CST

HSIC: 129.43 (+0.59)

Henry Schein beats Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:30AM CST
MELVILLE, N.Y. (AP) _ Henry Schein Inc. (HSIC) on Thursday reported third-quarter net income of $114.8 million.
HSIC: 129.43 (+0.59)

Henry Schein beats by $0.04, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:06AM CST

HSIC: 129.43 (+0.59)

Henry Schein Reports Record Third Quarter Results
PR Newswire - Thu Nov 06, 6:00AM CST
Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today reported record financial results for the quarter ended September 27, 2014.
HSIC: 129.43 (+0.59)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST

CYNI: 2.86 (+0.05), AAP: 144.73 (+2.88), DNOW: 27.38 (-0.62), AAON: 20.80 (-0.01), CNQ: 35.65 (-0.38), HSP: 56.07 (-0.25), CNK: 35.44 (+0.43), AMSC: 1.18 (+0.01), AES: 13.59 (+0.13), MWIV: 153.69 (-0.55), BBG: 13.11 (-0.64), HZNP: 13.14 (+0.15), KATE: 29.56 (-0.81), MITL: 9.85 (-0.08), AEE: 43.29 (-0.02), HSIC: 129.43 (+0.59), HII: 109.55 (+2.72), NAVB: 1.04 (-0.18), CECE: 14.91 (+0.69), AKRX: 35.81 (-0.78), COTY: 18.87 (+0.51), GOLD: 64.00 (-3.33), IT: 83.92 (+0.38), HNR: 3.02 (-0.15), KERX: 16.51 (-0.22), CECO: 5.56 (+0.08), HSC: 20.50 (-0.54), AMRC: 8.12 (-0.04), KLIC: 13.49 (-0.07), GEO: 40.74 (-0.66), AINV: 8.24 (-0.07), BCE: 45.63 (+0.65), AZN: 73.30 (+0.42), BCRX: 11.08 (+0.62), CPN: 24.30 (+0.06), BR: 44.98 (+0.54), FUR: 16.95 (unch), LIN: 23.75 (+0.03), LMIA: 12.87 (-0.25), CDW: 32.83 (+0.24), CVC: 18.61 (-0.31), AAWW: 41.50 (-0.19), GNRC: 40.68 (-0.18), MPEL: 25.25 (+0.48), DTV: 87.44 (+0.04), APA: 74.99 (-1.53), CRZO: 50.81 (-2.57), BKCC: 8.96 (+0.08), ERJ: 35.96 (-1.60), AMCX: 61.22 (-0.72), LPI: 18.37 (-0.71), HAIN: 108.96 (+1.28), FSYS: 9.13 (-0.30), GLP: 42.50 (+3.60), AOL: 44.23 (+1.55), FUN: 46.84 (-0.86), BDBD: 9.17 (+0.41)

What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 8.68 (-0.02), TROV: 4.79 (+0.14), PTCT: 41.42 (+1.18), HSIC: 129.43 (+0.59)

The Dr. Edward B. Shils Entrepreneurial Fund Recognizes Outstanding Innovators In Dentistry
PR Newswire - Tue Nov 04, 10:10AM CST
The Dr. Edward B. Shils Entrepreneurial Fund, Inc., a non-profit organization dedicated to innovative leadership in health care and named after the late Dr. Edward B. Shils, announced today the recipients of the 2014 Shils Awards. The Awards, which recognize individuals, organizations and programs that positively influence the dental community and the public oral health arena, were presented at the Shils Fund Dinner, held Oct. 29, at the Union League of Philadelphia in Philadelphia, Pa. Click here for photos of Award winners
HSIC: 129.43 (+0.59)

Henry Schein Larger Than S&P 500 Component Ralph Lauren
TheOnlineInvestor.com - Mon Nov 03, 3:52PM CST
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Henry Schein, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Ralph Lauren Corp , according to The...
HSIC: 129.43 (+0.59)

Will CVS Health (CVS) Keep its Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 2:30PM CST
CVS Health Corporation (CVS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 4.
AMSG: 51.69 (+0.19), CFN: 57.42 (+0.14), CVS: 88.99 (+0.61), HSIC: 129.43 (+0.59)

Will Covidien (COV) Disappoint Earnings Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 2:00PM CST
Covidien plc (COV) is set to report fourth-quarter fiscal 2014 results on Nov 5.
ACT: 246.03 (+0.12), MDT: 68.70 (+0.60), COV: 93.07 (+0.99), HSIC: 129.43 (+0.59)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 220

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 39

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

SoftBank Expands AI Infrastructure with DigitalBridge Deal

Updated Category News Views 109

SoftBank's Strategic Move in AI Infrastructure SoftBank Group Corp. has recently announced its plans to acquire DigitalBridge Group Inc. in a cash deal worth approximately $4 billion. This move is seen as a pivotal step in SoftBank's commitment to scaling its infrastructure capabilities for artificial intelligence globally. Details of the Acquisition Under the terms of...

Continue Reading
Nio's Bold Moves in the EV Space: What Investors Should Know

Updated Category News Views 158

Forget the Noise, Nio's Got a Game Plan Back in my day, when you heard whispers about a new product launch, it was either a cause for celebration or a catastrophe waiting to happen. Nio, the fast-rising EV player from China, is set to drop its ES9 SUV this May, and trust me, eyes are on the road. They’ve laid out the details like a clear roadmap. Mark Your Calendars Qin...

Continue Reading
Graycliff Partners Declares Landmark Structures Sale to Cerberus

Updated Category News Views 166

Graycliff Partners Announces the Sale of Landmark Structures Graycliff Partners LP has revealed its decision to sell Landmark Structures, an esteemed provider of water and industrial storage infrastructure solutions, to Cerberus Capital Management, a robust investment firm with a global reach. Landmark Structures specializes in designing, manufacturing, and installing...

Continue Reading
Wedbush Recognizes Uber Technologies as a Top Investment

Updated Category News Views 229

Wedbush Identifies Uber Technologies as a Prime Investment Opportunity In a recent analysis, Wedbush has included Uber Technologies Inc (NYSE: UBER) in its prestigious 'best ideas list.' This recognition stems from the company's attractive risk/reward dynamics, particularly as its shares are trading at a lower multiple. Valuation Insights Currently, Uber's stock is...

Continue Reading
Ververica Enhances Global Impact Through Innovative Partnerships

Updated Category News Views 161

Ververica's Global Influence in Real-Time Data Streaming Ververica, the pioneers behind Apache Flink®, recently highlighted its expanding global impact during the Flink Forward Jakarta event. This flagship occasion, known for focusing on cutting-edge data streaming technologies, served as an excellent platform for Ververica to demonstrate its dedication to helping...

Continue Reading